Evidence mapPaperPMID 42438233Full record

ArticleMicrobial biotechnology2026

Dual Silencing of Aminoglycoside Biosynthesis for the Discovery of Novel Antimicrobials in Streptomyces.

Yuncong Xu, Yali Du, Jiarong Yu, Yinghui Zhao, Zhenlin Li, Jufen Wang, Yijun Chen, Deli Xiao, Xuri Wu

Abstract read
In one paragraph

Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuncong XuDepartment of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.
Yali DuDepartment of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.
Jiarong YuDepartment of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.
Yinghui ZhaoDepartment of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.
Zhenlin LiDepartment of Pharmaceutical Analysis and Metabolomics, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu Province, People's Republic of China.
Jufen WangDepartment of Pharmacy, Jiangbei Campus of The First Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China.
Yijun ChenDepartment of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.
Deli XiaoDepartment of Analytical Chemistry, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.ORCID https://orcid.org/0000-0002-0778-4691
Xuri WuDepartment of Microbiology and Synthetic Biology, College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.ORCID https://orcid.org/0000-0002-0933-5902

Funding

Anti-Infective Drug Research and Development Project at China Pharmaceutical University YZZKY012Key Research and Development Project of Guangdong Province 2022B1111070004National College Students Innovation and Entrepreneurship Training Program 202510316037ZNational Natural Science Foundation of China 81973214
6 · The paper itself

Abstract

Streptomyces species are prolific sources of antimicrobials, yet their vast biosynthetic capacity remains underexploited due to the rediscovery of common antibiotics (e.g., ~1% for streptomycin and ~10% for streptothricin). To address this challenge, we developed a dual-layer biosynthetic blockade system, designated CI-ARS

Indexed as

AminoglycosidesAnti-Bacterial AgentsGene SilencingStreptomycesAcinetobacter baumanniiBiosynthetic PathwaysDrug DiscoveryMicrobial Sensitivity TestsMultigene FamilyAminoglycosidesAnti-Bacterial Agents

Identifiers

PMID42438233
PMCPMC13358218

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.